Mark Zobeck
@markzobeck.bsky.social
MD, MPH. Pediatric Hematologist/Oncologist & Clinical Data Scientist. Improving care for kids through causal and predictive modeling. ❤️ Bayes. www.thedoctorsdialectic.com
AI has caused an avalanche of pseudoscientific hype and magical thinking in clinical medicine. These tools have tremendous potential to help patients, but they are dangerous if we don't understand their limits.
www.thedoctorsdialectic.com/docs/posts/2...
#statistics #ai #machinelearning
www.thedoctorsdialectic.com/docs/posts/2...
#statistics #ai #machinelearning
The Doctor’s Dialectic - The Path to Useful and Trustworthy Clinical Prediction Models
www.thedoctorsdialectic.com
February 21, 2025 at 3:15 PM
AI has caused an avalanche of pseudoscientific hype and magical thinking in clinical medicine. These tools have tremendous potential to help patients, but they are dangerous if we don't understand their limits.
www.thedoctorsdialectic.com/docs/posts/2...
#statistics #ai #machinelearning
www.thedoctorsdialectic.com/docs/posts/2...
#statistics #ai #machinelearning
We have a paper out in JCO Precision Oncology describing new biomarkers for pediatric rhabdomyosarcoma!
- CDKN2A, MET, MYCN mutations associated with decreased survival.
- NF1 mutations associated with increased survival.
Read the full paper at ascopubs.org/doi/10.1200/...
- CDKN2A, MET, MYCN mutations associated with decreased survival.
- NF1 mutations associated with increased survival.
Read the full paper at ascopubs.org/doi/10.1200/...
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers | JCO Precision Oncology
PURPOSEMolecular markers increasingly influence risk-stratified treatment selection for pediatric
rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data to
produce individual...
ascopubs.org
February 7, 2025 at 4:59 PM
We have a paper out in JCO Precision Oncology describing new biomarkers for pediatric rhabdomyosarcoma!
- CDKN2A, MET, MYCN mutations associated with decreased survival.
- NF1 mutations associated with increased survival.
Read the full paper at ascopubs.org/doi/10.1200/...
- CDKN2A, MET, MYCN mutations associated with decreased survival.
- NF1 mutations associated with increased survival.
Read the full paper at ascopubs.org/doi/10.1200/...
Oncology trials, especially for pediatric patients, increasingly use external controls. But are these legitimate ways to evaluate a treatment effect?
I wrote a blog puzzling through this question.
https://buff.ly/4arKhTe
#oncology #statistics
I wrote a blog puzzling through this question.
https://buff.ly/4arKhTe
#oncology #statistics
The Doctor’s Dialectic - External Controls in Oncology Clinical Trials
Are these things legitimate?
buff.ly
January 21, 2025 at 3:44 PM
Oncology trials, especially for pediatric patients, increasingly use external controls. But are these legitimate ways to evaluate a treatment effect?
I wrote a blog puzzling through this question.
https://buff.ly/4arKhTe
#oncology #statistics
I wrote a blog puzzling through this question.
https://buff.ly/4arKhTe
#oncology #statistics